CJC-1295 no DAC

CJC-1295 no DAC Overview

CJC-1295 No DAC is a modified GHRH(1-29) analog incorporating four amino acid substitutions at positions 2, 8, 15, and 27 designed to confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation while preserving receptor binding affinity. Unlike the DAC-modified version with extended half-life, this variant maintains a shorter duration of action (approximately 30 minutes), enabling amplification of physiologic GH pulse patterns rather than sustained elevation. Research models examine its effects on pituitary GHRH receptor activation, growth hormone secretagogue activity, IGF-1 pathway stimulation, circadian GH rhythm modulation, and metabolic signaling in laboratory settings. Teichman et al. (2006). Alba et al. (2005)

History

CJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s as part of efforts to create GHRH analogs with improved pharmacokinetic properties. The original CJC-1295 with DAC (drug affinity complex) was designed for prolonged activity through albumin binding, reaching phase II experimental programs before discontinuation. The No DAC variant, retaining the core GHRH(1-29) modifications without the albumin-binding complex, emerged as a research tool for studying pulsatile signaling dynamics and has become widely utilized in somatotroph axis investigations.

Teichman et al. (2006).

CJC-1295 no DAC Structure

CAS #:

863288-34-0

Molecular Formula:

C₁₆₅H₂₆₉N₄₇O₄₆

Molecular Weight:

3647.28 g/mol

PubChem ID:

91976529